Lupus Research Alliance logo
LRA-Genentech Award on Immune Resetting Therapies for Lupus

LRA-Genentech Award on Immune Resetting Therapies for Lupus

Helps yr for pilot or mechanistic immune resetting research in lupus co-funded through the LRAGenentech Award on Immune Resetting Therapies for.

Between cyclesLupus Research AllianceUnited States
View on funder site
About

The LRA-Genentech Award on Immune Resetting Therapies for Lupus is a co-funded grant program supported by the Lupus Research Alliance (LRA) and Genentech, a leading biopharmaceutical company. The LRA, a New York 501(c)(3) (Federal Tax ID #58-2492929) with over $284 million distributed across 675+ grants, identified immune resetting as a core strategic priority in its 2024–2028 Research Roadmap, wh…

What this grant funds

Immune resetting therapies for lupus: one-year pilot projects on novel immune resetting technologies or methodologies, or two-year mechanistic research into current or emerging immune resetting therapies, co-funded with Genentech.

Key facts
CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.Annual
Next deadlineiThe next date applications are due. Rolling means you can apply any time.—
Decision timeiTypical time from the deadline to the funder's decision.—
Project durationiHow long the funded work is expected to run.12–24 months
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Grant
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.0%
Funding pooliThe total budget available across all awards in this round.—
Funding analytics

Sign up free to see the funding breakdown

Create free accountSign in
Industries

Sign up free to see the industries in scope

Create free accountSign in
Eligibility criteria

Sign up free to see the full eligibility

Create free accountSign in
Timeline

Sign up free to see the timeline

Create free accountSign in
Last verified: 24 Jul 2026Source: www.lupusresearch.org